13 terminated, 3 active not recruiting, 3 recruiting, 1 not yet recruiting. 16 Phase 1, 6 Phase 2, 2 Phase 3.
Follow Sasanlimab: new trials by email Literature Review of Sasanlimab trials Research Report on Sasanlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Pfizer | 294 | 2025-11-06 | 2026-10-13 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor Sasanlimab, non-ablative radiotherapy, [89Zr]Zr-crefmirlimab berdoxam - NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Radboud University Medical Center | 20 | 2025-02-01 | 2024-11-29 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Active not recruiting | Pfizer | 64 | 2024-06-27 | 2026-10-13 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) Sasanlimab, Palbocicilib - Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 100 | 2024-04-24 | 2026-10-16 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) PF-07225570, sasanlimab - Bladder Cancer | Phase 1 | Withdrawn | Pfizer | 2022-03-24 | 2023-03-08 | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors PF-07265028, Sasanlimab - Advanced Solid Tumors, Gastric Cancer | Phase 1 | Terminated | Pfizer | 21 | 2022-02-24 | 2026-02-19 |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion - Urothelial Carcinoma Bladder | Phase 2 | Active not recruiting | The Methodist Hospital Research Institute | 33 | 2022-02-15 | 2025-10-24 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors PF-07263689, Sasanlimab - Renal Cell Cancer, Melanoma | Phase 1 | Terminated | Pfizer | 13 | 2021-10-20 | 2024-04-12 |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) Sasanlimab Prefilled syringe, Encorafenib, Binimetinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Pfizer | 34 | 2020-11-10 | 2026-01-09 |
| Study of PF-07265807 in Participants With Metastatic Solid Tumors. PF-07265807, Sasanlimab, Axitinib - Neoplasm Metastasis | Phase 1 | Terminated | Pfizer | 88 | 2020-09-24 | 2026-06-04 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma | Phase 1 | Terminated | Seagen Inc. | 133 | 2020-05-29 | 2025-02-10 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Melanoma (9) · Carcinoma, Renal Cell (8) · Colorectal Neoplasms (8) · Urinary Bladder Neoplasms (7) · Lung Neoplasms (6) · Neoplasm Metastasis (6) · Squamous Cell Carcinoma of Head and Neck (6) · Neoplasms (5) · Kidney Neoplasms (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Ovarian Neoplasms (4) · Carcinoma, Pancreatic Ductal (3) · Head and Neck Neoplasms (3) · Stomach Neoplasms (3)
Pfizer (15) · National Cancer Institute (NCI) (1) · NiKang Therapeutics, Inc. (1) · Radboud University Medical Center (1) · Seagen Inc. (1) · Stephanie Berg (1) · The Methodist Hospital Research Institute (1)
United States (20) · Puerto Rico (5) · Spain (5) · Japan (4) · Canada (3) · France (3) · Italy (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Germany (2) · Poland (2) · South Korea (2) · China (1) · Israel (1)
Andres Forero-Torres, MD (1) · Dominik Sonanini, Dr. (1) · Raj Satkunasivam, MD (1) · Ramaprasad Srinivasan, M.D. (1) · Stephanie Berg, DO (1)
PMID 35703113, PMID 38189180, PMID 40450141, PMID 42008114, PMID 42177753
2019 (1), 2023 (1), 2025 (1)